Tissue microarray staining reveals PLD1 and Sp1 have a collaborative, pro-tumoral effect in patients with osteosarcomas
Metrics: PDF 1290 views | HTML 2337 views | ?
Xiao-Xu Wang1, Ying Liao2, Liang Hong1, Zhi Zeng1, Tang-Bo Yuan3, Xue Xia1 and Jian Qin3
1Department of Orthopaedics, The Second Affiliated Hospital of Nanhua University, Hengyang, Hunan, People’s Republic of China
2Department of Rehabilitation, The First Affiliated Hospital of Nanhua University, Hengyang, Hunan, People’s Republic of China
3Department of Orthopaedics, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
Jian Qin, email: [email protected]
Keywords: osteosarcoma, PLD1, Sp1, prognosis, immunohistochemistry
Received: March 08, 2017 Accepted: August 02, 2017 Published: September 01, 2017
It has been reported that phospholipase D1 (PLD1) - a key enzyme involved in lipid metabolism - is important for the initiation and progression of various human solid cancers; however, its biological significance and regulation in human osteosarcomas remain elusive. In this study, We found that PLD1 and Specificity Protein 1 (Sp1) expression were elevated in 137 osteosarcoma specimens with immunohistochemical staining. Our results showed that both PLD1 and Sp1 were expressed at much higher rates in the cancerous tissue compared to adjacent normal tissue. A correlation analyze also indicated that PLD1 was significantly associated with lactate dehydrogenase expression (p = 0.041) and the Enneking stage (p = 0.000), while Sp1 was significantly associated with the nuclear grade (p = 0.024). Furthermore, survival analyses showed that elevated PLD1 confers a poor prognosis on patients with osteosarcomas, acting as an independent prognostic factor. Of note, we showed a positive correlation between PLD1 and Sp1 expression in the cancer tissues (r = 0.357; p < 0.001). High co-expression of the two molecules results in the worst prognosis for the patients, and can also be regarded as independent prognostic factor (p = 0.001; HR = 2.71; 95% CI 1.53–4.80).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.